Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Poeya HaydarlouDepartment of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Cardiomyopathy & Arrhythmia, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.ORCID http://orcid.org/0009-0000-3938-3377
Daria R KramarenkoDepartment of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Cardiomyopathy & Arrhythmia, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Marie KlevjerDepartment of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.ORCID http://orcid.org/0000-0001-8372-276X
Oliver B VadDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Marre E CorverDepartment of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Cardiomyopathy & Arrhythmia, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Dominic S ZimmermanDepartment of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Cardiomyopathy & Arrhythmia, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
BioBank Japan Project
Koichi MatsudaLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-7292-2686
Søren Z DiederichsenDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-9687-0857
Anja ByeDepartment of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Jesper H SvendsenDepartment of Cardiology, The Heart Centre, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-8466-8515
Kaoru ItoLaboratory for Cardiovascular Genomics and Informatics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.ORCID http://orcid.org/0000-0003-1843-773X
Patrick T EllinorCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Connie R Bezzina *Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Cardiomyopathy & Arrhythmia, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands. c.r.bezzina@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-0633-3514
Sean J Jurgens *Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, Cardiomyopathy & Arrhythmia, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands. s.j.jurgens@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-1605-9782
Funding
IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6M
Using Electrocardiogram Genetics to Inform Arrhythmia RiskR01HL157635 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS, MIRSHAHI, TOORAJ · 2022 to 2025
$2.9M
Mentoring in Arrhythmia ResearchK24HL105780 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS · 2011 to 2020
$1.2M
American Heart Association (American Heart Association, Inc.) 18SFRN34110082American Heart Association (American Heart Association, Inc.) 18SFRN34110082, 961045American Heart Association (American Heart Association, Inc.) 961045American Heart Association (American Heart Association, Inc.) Postdoctoral FellowshipFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) 1RO1HL092577Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) K24HL105780Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) R01HL157635Hartstichting (Dutch Heart Foundation) 03-007-2022-0035Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) KIC PRECISENHLBI NIH HHS K24 HL105780NHLBI NIH HHS R01 HL092577NHLBI NIH HHS R01 HL157635
6 · The paper itself
Abstract
Polygenic scores can improve atrial fibrillation risk prediction. However, limited accuracy and cross-ancestry transferability hinder clinical translation. Here, we explore several ensemble approaches to generate ancestry-optimized polygenic scores, with development in diverse participants from the All of Us Research Program, BioBank Japan, and three additional cohorts. Our ancestry-specific multi-trait approach particularly improves prediction in South-Asian (odds-ratio/standard deviation 1.5-1.8; area under curve 0.60-0.64; relative R² +71%), Admixed-American (1.5; 0.60; +34%) and African ancestry groups (1.4; 0.57; +56%). Nevertheless, performance remains highest in European and East-Asian ancestries (1.8-2.2; 0.65-0.68), where >50% of SNP-heritability is explained. Improved risk stratification is also observed at the extremes, identifying European and East-Asian ancestry individuals with risk comparable to rare TTN variants (e.g., 6-11% with >4-fold odds). Finally, our scores improve incident risk prediction alongside clinical models. Together, we show that our ancestry-tailored multi-trait polygenic scores advance atrial fibrillation risk prediction and stratification, providing an equitable foundation for implementation.
Indexed as
Atrial FibrillationGenetic Predisposition to DiseaseMultifactorial InheritanceAsian PeopleBlack PeopleConnectinFemaleGenetic Risk ScoreGenome-Wide Association StudyGenomicsHumansJapanMaleMiddle AgedPolymorphism, Single NucleotideWhite PeopleConnectin
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Multi-trait polygenic risk scores improve genomic prediction of atrial fibrillation across diverse ancestries. · full record | OpenQuestion